Full Press Release Details
Therapeutics Announces Activation of Clinical Trial Sites in
South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
First patient in South Korea dosed --
FL., September 16, 2025 (GLOBE NEWSWIRE) - Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"),
a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced activation of
two South Korean clinical trial sites participating in its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics
(PK) and pharmacodynamics (PD) of PAS-004, in adult participants with neurofibromatosis type 1 (NF1) with symptomatic and inoperable,
incompletely resected, or recurrent plexiform neurofibromas.
South Korea clinical trial sites, ASAN Medical Centre and Severance Hospital Yonsei University Health System, are now actively recruiting
NF1 trial participants.
Lee Beom-Hee of the Department of Pediatrics at Asan Medical Center said, "I am very pleased to partner with the Pasithea team
to initiate testing of PAS-004 in adult patients with plexiform neurofibromas associated with NF1 at Asan Medical Center. Our institution
has the largest NF1 caseload in South Korea and a long history of research leadership in this field. Our team was among the first to
report the therapeutic benefits of MEK inhibition on neurocognitive decline, caf -au-lait spots, and growth retardation caused
by neurofibromatosis. We are eager to evaluate PAS-004, a next-generation MEK inhibitor that to date has demonstrated a distinct pharmacokinetic
profile and a more convenient dosing regimen, which we believe may provide important benefits for our NF1 patients."
Tiago Reis Marques, chief executive officer of Pasithea commented, "With access to world-class facilities and an estimated 10,000
NF1 patients in South Korea, we believe our clinical sites in the country will play a pivotal role in the success of this trial. We are
excited to include South Korean patients in our NF1 study and look forward to advancing meaningful treatment options for this community."
Medical Center is a reference hospital and the teaching hospital of the University of Ulsan College of Medicine, located in Seoul, South
Korea. With 2,432 beds for patients and a total floor area of approximately 280,000 square meters, it is the largest hospital in South
Hospital is a teaching hospital located in Sinchon-dong, Seodaemun District, South Korea. It is one of the oldest and biggest university
hospitals in South Korea. It has 2,437 beds and treats approximately 2,500,000 outpatients and 840,000 inpatients annually.
the Phase 1/1b Clinical Trial in Adult NF1 Patients
primary objective of the Phase 1/1b study (NCT06961565) is to evaluate the safety and tolerability of PAS-004 when administered
for one 28-day treatment cycle in adult NF1 participants with at least one and up to two additional target plexiform neurofibromas (PNs)
that are symptomatic and inoperable, incompletely resected, or recurrent. Secondary objectives are (i) to identify the recommended Part
B dose ("RPBD") or Maximum Tolerated Dose (MTD) of PAS-004, (ii) to characterize the PK and PD profile of PAS-004, (iii)
to evaluate the preliminary efficacy of PAS-004 on target PN volume, (iv) to evaluate the preliminary efficacy of PAS-004 on the size,
appearance, and associated symptoms of cutaneous neurofibromas (CNs), and (v) to evaluate the impact of PAS-004 on quality of life ("QOL")
and any physical symptoms attributed to the target PN. Experimental objectives are (i) to evaluate the impact of PAS-004 on QOL and any
physical symptoms attributed to CNs, (ii) to evaluate the impact of PAS-004 on pain and function attributed to PNs, and (iii) to investigate
PAS-004 effects on CN tumor cellular and molecular biology.
trial will be conducted in two parts. In Part A (dose escalation phase), following a screening period of up to 28 days, up to 24 eligible
participants will be enrolled sequentially to receive one of four planned dose levels of PAS-004 tablets (4mg, 8mg, 12mg, 18mg) in a
modified 3+3 design. Part A will identify the recommended RPBD. During Part B (expansion phase), approximately 24 eligible participants
will be enrolled in parallel to receive one of two planned dose levels of PAS-004 tablets. Participants will be dosed at the RPBD level
and at a dose level below the RPBD for up to six continuous 28-day treatment cycles. Part B will identify the recommended phase 2 dose
study is planned to be conducted at five clinical trial sites in Australia, South Korea and the U.S.
Pasithea Therapeutics Corp.
is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation
macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently
testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients
with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).
press release contains statements that constitute "forward-looking statements" made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company's
ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company's Phase 1/1b clinical trial of PAS-004 in adult
patients with NF1-associated plexiform neurofibromas, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary
efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company's current
views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company's
plans, assumptions, expectations, beliefs and objectives, the success of the Company's current and future business strategies,
product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position,
business strategies, potential growth opportunities and other statements that are predictive in nature. Forward-looking statements are
subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking
statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information
available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions
and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed
to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well
as other factors set forth in the Company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings
made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes
no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release,
except as required by law.
Therapeutics Contact
Corporate Communications